• CRISPR Therapeutics reported rapid commercial expansion of Casgevy, its FDA approved gene editing treatment for sickle cell disease, with patient initiations nearly tripling year over year.
• Coverage and reimbursement for Casgevy now extend across much of the US, Europe, and the Middle East, reaching a majority of eligible patients.
• The company is progressing in vivo gene editing programs targeting cardiovascular and autoimmune diseases, as well as oncology, adding momentum beyond recent earnings updates.

CRISPR Therapeutics, listed as NasdaqGM:CRSP, is drawing fresh attention as Casgevy moves from approval into broader real world use. The share price sits at $53.17, with the stock up 10.0% over the past week and essentially flat over 1 year. Over a longer period, the 5 year return of a 60.2% decline highlights how volatile sentiment around gene editing can be.

For investors watching CRISPR Therapeutics, the focus is now on how Casgevy uptake and reimbursement progress alongside the in vivo pipeline in cardiovascular, autoimmune, and oncology programs. The combination of active commercial rollout and a broader development portfolio provides multiple sets of milestones to track as the company advances its gene editing approach.

Stay updated on the most important news stories for CRISPR Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on CRISPR Therapeutics.

For you as an investor, the key takeaway is that Casgevy is moving from a story about regulatory approval to one about commercial reach. While CRISPR Therapeutics reported full year 2025 revenue of US$3.51 million and a net loss of US$581.6 million, partner disclosures and analyst commentary point to Casgevy sales of about US$116 million in 2025, with Vertex Pharmaceuticals guiding to higher non cystic fibrosis revenue that includes this product. That disconnect between reported revenue and broader franchise sales reflects the structure of the Vertex partnership, so the focus is less on headline quarterly figures and more on patient initiations, reimbursement coverage and the pace of treatment center onboarding. Compared with competitors such as Vertex itself, Bluebird Bio and other gene therapy players, rapid access across the US, Europe and the Middle East helps CRISPR Therapeutics defend share in sickle cell disease while it works on in vivo programs like CTX310, CTX321 and CTX611 and cell therapy candidate zugo cel. For a company that currently does not have meaningful revenue and is loss making, this kind of commercial traction and pipeline breadth is central to the longer term equity story.

The Risks and Rewards Investors Should Consider

• ⚠️ CRISPR Therapeutics is currently unprofitable, with a full year 2025 net loss of US$581.6 million and a basic loss per share of US$6.47, which may require ongoing funding to support operations.
• ⚠️ The company does not yet have meaningful revenue, reporting US$3.51 million for 2025, so its financial profile is heavily dependent on future product uptake and partnership economics.
• 🎁 Analysts highlight that revenue is forecast to grow rapidly, which, if realized, would increase the company’s scale relative to its current financial base.
• 🎁 Shares are described as trading well below some estimates of fair value, which some investors may see as room for upside if execution on Casgevy and the broader pipeline continues.

What To Watch Going Forward

From here, you may want to watch how fast Casgevy moves from patient initiations to completed treatments, and how revenue sharing with Vertex translates into reported top line for CRISPR Therapeutics. Uptake trends in new regions, additional reimbursement wins and the opening of more authorized treatment centers are all practical markers of how entrenched Casgevy is becoming versus alternatives from players like Bluebird Bio. On the pipeline side, progress updates on in vivo cardiovascular and autoimmune programs, as well as oncology assets such as zugo cel, will show whether the company can build a multi product portfolio rather than relying on a single therapy. Cash burn and any changes to guidance on how long existing capital will fund operations are also worth tracking, given the current loss making profile.

To ensure you're always in the loop on how the latest news impacts the investment narrative for CRISPR Therapeutics, head to the community page for CRISPR Therapeutics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.